X
[{"orgOrder":0,"company":"Meabco","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","amount":"$5.9 million","upfrontCash":"Undisclosed","newsHeadline":"Meabco Gets $5.9 M US Government Contract to Advance Its Bp-C2 Compound for Cutaneous Radiation Injuries","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"DENMARK","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Meabco"},{"orgOrder":0,"company":"Meabco","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Meabco's Drug Candidate Efficiently Mitigates Radiation-Induced Gastrointestinal Syndrome in Mice","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Preclinical","country":"DENMARK","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Meabco"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
Details:
BP-C2 reduces mortality when administered 24 hours post-exposure in a murine model of severe, radiation-induced gastrointestinal acute radiation syndrome (GI-ARS).
Lead Product(s):
BP-C2
Therapeutic Area: Trauma (Emergency, Injury, Surgery)
Product Name: BP-C2
Highest Development Status: Preclinical
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
October 19, 2020
Details:
This three-year contract consists of a one-year base period with two one-year optional periods that will allow Meabco to complete IND-enabling studies and advance BP-C2 as a therapy for treating the effects of unintentional radiation exposure.
Lead Product(s):
BP-C2
Therapeutic Area: Trauma (Emergency, Injury, Surgery)
Product Name: BP-C2
Highest Development Status: Preclinical
Product Type: Small molecule
Partner/Sponsor/Collaborator:
National Institutes of Health
Deal Size: $5.9 million
Upfront Cash: Undisclosed
Deal Type: Funding
May 25, 2020